Endometriosis After Hysterectomy: Why Symptoms Persist and How to Treat Them
Yoon Hang Kim, MD, MPH
Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician
For many women living with endometriosis, hysterectomy is offered — and often accepted — as the "definitive" solution to years of debilitating pelvic pain. Yet a meaningful number of women are dismayed to discover that pain, pressure, or bowel and bladder symptoms continue after the uterus is gone. This is not a failure of the woman's body, nor is it imaginary. It reflects a fundamental truth about the disease: endometriosis is not a disease of the uterus. Understanding why symptoms persist after hysterectomy — and what can be done about them — is essential to charting a realistic and effective path forward.
In an integrative and functional medicine practice, these clients are among the most complex and the most underserved. They frequently arrive after multiple surgeries, having been told there is "nothing more to do." There is, in fact, a great deal that can be done. This article reviews the evidence on why endometriosis recurs or persists after hysterectomy and outlines conventional, hormonal, and integrative treatment strategies grounded in the published literature.
Hysterectomy Is Not a Cure for Endometriosis
Endometriosis is defined by the presence of endometrial-like glands and stroma outside the uterine cavity — on the ovaries, pelvic peritoneum, bowel, bladder, ureters, and, in deep infiltrating disease, within the tissues between the vagina and rectum. Removing the uterus addresses the organ where menstrual bleeding originates, but it does not remove disease that lives elsewhere in the pelvis. This distinction explains why hysterectomy can reduce, but does not reliably eliminate, endometriosis-associated pain.
The scale of the problem is significant. In the United States, more than 100,000 hysterectomies are performed each year with a primary diagnosis of endometriosis, and roughly 12% of women with the disease will eventually undergo the procedure. Yet hysterectomy is not a guarantee of relief. In a 2025 JAMA review, approximately 25% of women who underwent hysterectomy for endometriosis experienced recurrent pelvic pain, and about 10% underwent additional surgery to address it. Endometriosis behaves as a chronic, estrogen-dependent, inflammatory disease that frequently requires sustained management rather than resolution through a single definitive operation.
Incomplete Excision: The Leading Cause of Recurrence
A comprehensive review of the literature on recurrence after hysterectomy identified incomplete excision of endometriotic lesions as the single most predominant reason symptoms return. If deep or peritoneal disease is left behind at the time of surgery — which is common when the operation focuses on removing the uterus rather than meticulously excising all visible and palpable endometriosis — the disease process simply continues. The type of hysterectomy matters chiefly because it influences how thoroughly the surrounding lesions are addressed.
Ovarian Conservation and the Role of Estrogen
Because endometriosis is an estrogen-dependent condition, whether the ovaries are retained profoundly affects recurrence risk. A landmark historical cohort from Johns Hopkins followed 138 women who underwent hysterectomy for endometriosis. The contrast between those who retained ovarian tissue and those who did not was striking:
Data from Namnoum et al., Fertil Steril 1995. Ovarian conservation was associated with a 6.1-fold higher risk of recurrent pain and an 8.1-fold higher risk of reoperation.
These figures do not mean every woman should have her ovaries removed — oophorectomy carries its own substantial consequences, particularly in younger women, including accelerated bone loss, cardiovascular risk, and the abrupt onset of surgical menopause. Rather, they underscore that retained ovaries continue to produce the estrogen that fuels any residual disease.
Estrogen Beyond the Ovaries
A crucial and often overlooked point is that endometriosis can persist even after both ovaries are removed. Estrogen is not made only by the ovaries. Adipose (fat) tissue, the adrenal glands, skin, and even the endometriotic lesions themselves can produce estrogen through the enzyme aromatase. Endometriotic implants have been shown to express aromatase locally, allowing them to generate their own estrogen supply and sustain themselves in a low-estrogen environment. This local hormonal autonomy is precisely why some women experience recurrence after what was described as "definitive" surgery, and it forms the biological rationale for aromatase-targeted therapy discussed below.
Evaluating Persistent Symptoms After Hysterectomy
When a client reports ongoing pelvic pain, painful intercourse, cyclical bowel or bladder symptoms, or a palpable pelvic mass after hysterectomy, a careful and open-minded evaluation is warranted. Persistent symptoms should never be automatically attributed to "something else" simply because the uterus has been removed. A thoughtful workup may include a detailed symptom and surgical history, pelvic examination, transvaginal or abdominal ultrasound, and — where deep infiltrating disease is suspected — pelvic MRI. Because pelvic pain is often multifactorial, evaluation should also consider pelvic floor dysfunction, adhesions, nerve entrapment, interstitial cystitis, and central sensitization, all of which frequently coexist with endometriosis and can perpetuate pain independently.
Conventional Treatment Options
Conventional management of endometriosis follows a stepwise ladder that escalates from hormonal suppression to surgery. After hysterectomy, this same framework governs the treatment of any residual or recurrent disease, adapted to the surgical context: with the uterus absent, therapy centers on suppressing estrogen stimulation of remaining lesions, controlling inflammation, and — when appropriate — excising disease that was left behind. A network meta-analysis of hormonal therapies found that combined contraceptives, progestins, and GnRH agonists all produced broadly similar, clinically meaningful pain reduction, so the choice among them is guided largely by side-effect profile, cost, and individual response rather than by clear superiority of any single agent. Because the disease is chronic, an estimated 25% to 34% of women experience recurrent pelvic pain within 12 months of stopping hormonal therapy, underscoring that suppression is typically a long-term strategy.
First-Line: NSAIDs and Hormonal Suppression
First-line therapy pairs nonsteroidal anti-inflammatory drugs (NSAIDs) for symptomatic relief with hormonal suppression. In women who retain their ovaries after hysterectomy, continuous combined estrogen–progestin therapy or progestin-only agents suppress residual lesions. Common progestin options include norethindrone acetate (2.5–15 mg daily), dienogest (2 mg daily), depot medroxyprogesterone acetate (150 mg intramuscularly every three months), and the etonogestrel implant. These agents are low-cost, generally well tolerated, and readily managed in a primary care or integrative practice setting. The levonorgestrel intrauterine system, a mainstay when the uterus is present, is no longer an option once the uterus has been removed.
Second-Line: GnRH Agonists and Antagonists
When first-line therapy is insufficient, GnRH agonists and antagonists suppress ovarian estrogen production more profoundly. GnRH agonists — such as leuprolide (3.75 mg monthly or 11.25 mg every three months), nafarelin nasal spray, or goserelin — should be paired with add-back therapy (for example, norethindrone acetate 5 mg daily) started concurrently to protect bone density and reduce vasomotor symptoms. Oral GnRH antagonists offer a newer, more convenient approach: elagolix (150 mg daily or 200 mg twice daily) and relugolix combination therapy (relugolix 40 mg with estradiol 1 mg and norethindrone acetate 0.5 mg, marketed as Myfembree), which builds the protective add-back hormones into a single daily tablet.
Third-Line: Aromatase Inhibitors
Aromatase inhibitors such as letrozole (2.5–7.5 mg daily) represent third-line therapy and carry particular relevance after hysterectomy. Because they block estrogen production at extraovarian sites — including within the endometriotic lesions themselves — they are among the few agents capable of addressing disease that persists even after the ovaries have been removed. In women who still have functioning ovaries, an aromatase inhibitor is combined with a progestin to prevent reflex ovarian stimulation. Their use is generally reserved for refractory cases, since sustained estrogen suppression reduces bone density and requires ongoing monitoring.
Expert Surgical Excision of Residual Disease
When residual or recurrent endometriosis is identified, meticulous surgical excision by a surgeon experienced in advanced endometriosis is often the most effective intervention. The goal is complete removal of all disease, including deep infiltrating lesions involving the bowel, bladder, or ureters — a technically demanding undertaking that differs substantially from a standard hysterectomy. Because incomplete excision is the leading driver of recurrence, referral to a high-volume excision specialist is frequently the single most valuable step for a woman with persistent disease. Following any excisional surgery, postoperative hormonal suppression is recommended to reduce the risk of recurrence. A suspicious endometriotic mass in a postmenopausal or post-surgical woman warrants surgical evaluation first, given a small but real risk of malignant transformation.
The Hormone Replacement Therapy Dilemma
Women who undergo removal of both ovaries — especially those under 45 — enter abrupt surgical menopause, with a sudden loss of estrogen that can produce severe hot flashes, bone loss, cardiovascular risk, and quality-of-life decline. Hormone therapy until at least the natural age of menopause is generally recommended to protect long-term health. Yet in a woman with a history of endometriosis, exogenous estrogen carries a theoretical risk of reactivating residual disease and a small risk of malignant transformation.
The literature offers guidance, though the evidence base is limited. A Cochrane review concluded that hormone therapy may increase the risk of symptomatic recurrence after surgically induced menopause, and that if residual disease is present, unopposed estrogen is best avoided. International guidance from the European Menopause and Andropause Society advises that estrogen-only therapy should be avoided even in women who have had a hysterectomy, with continuous combined estrogen–progestogen regimens (or tibolone) preferred to reduce the risk of recurrence and malignant transformation of any residual lesions. The practical takeaway is that hormone therapy in this setting is neither automatically unsafe nor automatically appropriate; it requires individualized, shared decision-making that weighs menopausal symptom burden and long-term health against disease-reactivation risk.
An Integrative and Functional Medicine Framework
Conventional surgical and hormonal therapies address the estrogen dependence and anatomic burden of endometriosis, but they do not fully account for the chronic inflammation and central pain sensitization that often persist after hysterectomy. A functional medicine approach layers evidence-informed strategies onto standard care to target these drivers and to support the whole person. These measures are complementary, not a replacement for appropriate surgical or medical treatment.
Low-Dose Naltrexone (LDN)
Low-dose naltrexone has emerged as a rational option for endometriosis-associated pain, particularly where central sensitization is prominent. At doses far below those used for addiction treatment, naltrexone appears to act as a glial-cell modulator in the central nervous system, dampening the release of pro-inflammatory cytokines and reducing pain sensitivity — mechanisms independent of its classical opioid-blocking action. LDN has demonstrated benefit in related inflammatory and centralized pain conditions such as fibromyalgia and Crohn's disease, and it is inexpensive and generally well tolerated, with vivid dreams being the most commonly reported side effect. It is important to be candid that robust randomized trials specifically in endometriosis are still lacking; LDN is best framed as a monitored, individualized trial aimed at symptom modulation rather than a proven cure.
Anti-Inflammatory Nutrition
Endometriosis is fundamentally an inflammatory condition, and diet is a modifiable lever. Population data link a highly pro-inflammatory dietary pattern to increased endometriosis risk, while diets rich in fruits, vegetables, whole grains, legumes, and olive oil — the Mediterranean pattern — are associated with lower risk and may help moderate estrogen levels through increased sex-hormone-binding globulin. Omega-3 fatty acids (EPA and DHA) inhibit pro-inflammatory prostaglandin formation and have been associated in retrospective data with greater pain improvement and reductions in inflammatory markers when added to conventional therapy. Polyphenols such as resveratrol have shown anti-inflammatory and anti-angiogenic properties in the research literature, though clinical evidence remains preliminary.
Supporting Estrogen Metabolism and Lifestyle
Because adipose tissue is a significant source of aromatase-driven estrogen after oophorectomy, supporting a healthy body composition can meaningfully influence the hormonal environment. Additional lifestyle factors with biological plausibility include minimizing exposure to endocrine-disrupting chemicals, moderating alcohol intake, prioritizing restorative sleep, and actively managing psychological stress — all of which modulate the inflammatory and hormonal pathways relevant to the disease. Selected micronutrients and supplements, including vitamin D, magnesium, N-acetylcysteine, and curcumin, show promising but variable evidence and are best individualized rather than applied uniformly.
Addressing Central Sensitization and Pelvic Floor Dysfunction
After years of pelvic pain and multiple surgeries, many women develop pelvic floor muscle dysfunction and central sensitization — a rewiring of the nervous system that amplifies pain signals. In these clients, no amount of estrogen suppression will fully resolve symptoms unless the nervous system and musculature are addressed. Pelvic floor physical therapy, graded movement, and modalities that calm an over-active pain response are important components of a comprehensive plan, and they help explain why a multidisciplinary, whole-person strategy so often outperforms any single intervention.
A Personalized Path Forward
The woman with persistent endometriosis symptoms after hysterectomy is not out of options — she is at the beginning of a more nuanced conversation. Effective care typically integrates several elements: confirming whether residual or deep disease is present, considering expert excision when it is, thoughtfully navigating hormone therapy in surgical menopause, and layering anti-inflammatory, neuromodulatory, and lifestyle strategies to address the inflammation and central sensitization that surgery alone cannot reach. The most durable results come from combining the best of conventional gynecologic care with an integrative framework tailored to the individual.
For clients seeking an integrative and functional medicine approach to persistent endometriosis symptoms, individualized evaluation and care are available through www.directintegrativecare.com.
Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice. It is not a substitute for individualized evaluation, diagnosis, or treatment by a qualified healthcare professional. Endometriosis and post-surgical care are highly individual; treatment decisions — including the use of hormone therapy, aromatase inhibitors, low-dose naltrexone, supplements, or additional surgery — should be made in consultation with your own physician. Never disregard professional medical advice or delay seeking it because of information you have read here.
About Dr. Kim
Dr. Yoon Hang "John" Kim is a board-certified physician with more than 20 years of experience in integrative and functional medicine. He completed his fellowship in integrative medicine at the University of Arizona under Dr. Andrew Weil and holds board certifications in Preventive Medicine as well as Integrative and Holistic Medicine, along with certification in medical acupuncture. Dr. Kim specializes in low-dose naltrexone (LDN), autoimmune conditions, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome (MCAS), and mold toxicity. He is the author of three books and more than 20 articles.
Professional website: www.yoonhangkim.com | Clinical practice: www.directintegrativecare.com
References
1. As-Sanie S, Mackenzie SC, Morrison L, Schrepf A, Zondervan KT, Horne AW, Missmer SA. Endometriosis: A Review. JAMA. 2025;334(1):64-78. doi:10.1001/jama.2025.2975. PMID: 40323608.
2. Rizk B, Fischer AS, Lotfy HA, et al. Recurrence of endometriosis after hysterectomy. Facts Views Vis Obgyn. 2014;6(4):219-227. PMID: 25593697.
3. Namnoum AB, Hickman TN, Goodman SB, Gehlbach DL, Rock JA. Incidence of symptom recurrence after hysterectomy for endometriosis. Fertil Steril. 1995;64(5):898-902. PMID: 7589631.
4. Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med. 2020;382(13):1244-1256. doi:10.1056/NEJMra1810764.
5. Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. Lancet. 2021;397(10276):839-852. doi:10.1016/S0140-6736(21)00389-5.
6. Edi R, Cheng T. Endometriosis: Evaluation and Treatment. Am Fam Physician. 2022;106(4):397-404.
7. Alonso A, Gunther K, Maheux-Lacroix S, Abbott J. Medical management of endometriosis. Curr Opin Obstet Gynecol. 2024;36(5):353-361. doi:10.1097/GCO.0000000000000983.
8. Chen I, Veth VB, Choudhry AJ, et al. Pre- and postsurgical medical therapy for endometriosis surgery. Cochrane Database Syst Rev. 2020;11:CD003678. doi:10.1002/14651858.CD003678.pub3.
9. Polyzos NP, Fatemi HM, Zavos A, et al. Aromatase inhibitors in post-menopausal endometriosis. Reprod Biol Endocrinol. 2011;9:90. PMID: 21693039.
10. Ferrero S, Gillott DJ, Venturini PL, Remorgida V. Use of aromatase inhibitors to treat endometriosis-related pain symptoms: a systematic review. Reprod Biol Endocrinol. 2011;9:89.
11. Zanello M, Borghese G, Manzara F, et al. Hormonal Replacement Therapy in Menopausal Women with History of Endometriosis: A Review of Literature. Medicina (Kaunas). 2019;55(8):477. doi:10.3390/medicina55080477.
12. Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a history of endometriosis: a systematic review. Hum Reprod Update. 2017;23(4):481-500.
13. Erel CT, Nigdelis MP, Ozcivit Erkan IB, et al. Endometriosis and menopausal health: An EMAS clinical guide. Maturitas. 2025;202:108715. doi:10.1016/j.maturitas.2025.108715.
14. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. PMID: 24526250.
15. Sienko A, Cichosz A, Urban A, Smolarczyk R, Czajkowski K, Sienko J. The effect of two anti-inflammatory dietary components, omega-3 and resveratrol, on endometriosis. Ginekol Pol. 2024;95(7):573-583. PMID: 37768015.
16. The Role of Lifestyle and Diet in the Treatment of Endometriosis: A Review. Nutrients. 2026;18(1):142. doi:10.3390/nu18010142.
17. Becker CM, Bokor A, Heikinheimo O, et al. ESHRE guideline: endometriosis. Hum Reprod Open. 2022;2022(2):hoac009.
